GO:0006218 uridine catabolic process: Genes & Methods

Uridine is a ribonucleoside that is widely distributed in cells but occurs almost entirely as phosphoric esters within ribonucleotides and ribonucleic acids. The Gene Ontology term GO:0006218, uridine catabolic process, defines the chemical reactions and pathways that result in the breakdown of uridine. This process is distinct from pyrimidine biosynthesis and salvage, and it determines the cellular pool of uridine available for RNA synthesis, post-transcriptional modification, and glycosylation reactions. Understanding uridine catabolism is therefore central to studies of nucleotide homeostasis, RNA modification, and metabolic control of immune cell function. Recent work has shown that uridine depletion impairs CD8+ T cell antitumor activity through N-glycosylation, directly tying uridine catabolic flux to immune surveillance. In parallel, incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation, demonstrating that modified uridine species influence protein synthesis. tRNA modification enzymes that act on uridine derivatives regulate redox homeostasis and synapse formation, linking uridine catabolism to neuronal function and memory. Uridine also potentiates aminoglycosides through activation of carbohydrate transporters, indicating that uridine availability can be pharmacologically manipulated. For researchers, GO:0006218 provides a precise framework to interrogate how uridine is degraded, which enzymes and transporters are involved, and how this pathway intersects with disease. The clinical relevance of uridine catabolism is exemplified by decitabine and cedazuridine combination therapy, where cedazuridine inhibits cytidine deaminase to increase decitabine exposure. This article synthesizes authoritative QuickGO annotation and verified PubMed literature to describe the mechanism, key genes, disease links, and experimental models for studying uridine catabolic process.

GO:0006218 (uridine catabolic process) is the biological process comprising the chemical reactions and pathways that result in the breakdown of uridine, uracil riboside, a ribonucleoside very widely distributed but occurring almost entirely as phosphoric esters in ribonucleotides and ribonucleic acids. Synonyms include uridine breakdown, uridine catabolism, and uridine degradation. The term covers enzymatic steps that convert uridine into downstream catabolic products, thereby regulating the cellular uridine pool and influencing RNA modification, glycosylation, and nucleotide salvage.

Uridine catabolic process is important because it controls the availability of uridine for RNA synthesis, post-transcriptional modification, and glycosylation, thereby influencing translation, immune cell function, and neuronal physiology. Dysregulation of uridine metabolism can impair antitumor immunity, alter mRNA translation efficiency, and affect synaptic function and memory. Pharmacological inhibition of uridine catabolism, as with cedazuridine, is already used clinically to modulate drug exposure. Thus, GO:0006218 provides a mechanistic entry point for understanding metabolic control of gene expression and for developing therapeutic strategies.

The following genes and proteins are experimentally implicated in uridine catabolic process and its regulatory network, based on verified PubMed literature.

Uridine catabolic process is regulated at multiple levels. mTORC1 cooperates with tRNA wobble modification to sustain the protein synthesis machinery, linking nutrient signaling to uridine derivative utilization. Elongator complex subunits (ELP1-ELP6) acetylate tRNA bases, and their activity is required for proper wobble uridine modification. Guide RNA acrobatics and one-for-two shuffling mechanisms illustrate dynamic RNA modification events that can influence uridine-related pathways. Uridine depletion impairs CD8+ T cell antitumor activity through N-glycosylation, indicating that immune activation signals can alter uridine catabolic flux. Pharmacological regulation is exemplified by cedazuridine, which inhibits cytidine deaminase and thereby modulates pyrimidine metabolism. Together, these layers ensure that uridine breakdown is coordinated with translation, redox balance, and immune function.

Uridine depletion impairs CD8+ T cell antitumor activity through N-glycosylation, directly linking uridine catabolic process to cancer immunosurveillance. Tumors may alter uridine metabolism to evade immune attack, and targeting uridine catabolic enzymes could modulate T cell function. Additionally, cedazuridine is used clinically with decitabine in myelodysplastic syndromes and acute myeloid leukemia, demonstrating that pyrimidine catabolism inhibitors have therapeutic value.

tRNA modification enzyme-dependent redox homeostasis regulates synapse formation and memory, implicating uridine catabolic and modification pathways in neuronal function. Deficiencies in CTU1/CTU2 and related enzymes can disrupt uridine thiolation, leading to oxidative stress and synaptic defects. These findings suggest that uridine catabolic process is relevant to neurodegenerative conditions and cognitive disorders.

Pseudouridine incorporation into mRNA enhances translation by diminishing PKR activation, and dysregulation of pseudouridine synthases such as DKC1 is associated with ribosomopathies. Because uridine is a precursor for pseudouridine, altered uridine catabolism may contribute to translation-related diseases. mTORC1 cooperation with tRNA wobble modification further ties uridine metabolism to protein synthesis machinery and growth control.

Uridine potentiates aminoglycosides through activation of carbohydrate transporters, indicating that uridine availability affects drug response. Cedazuridine inhibition of cytidine deaminase increases decitabine exposure, showing that uridine catabolic enzymes are druggable. These examples highlight the clinical importance of uridine catabolic process in metabolic and pharmacological contexts.

Stable isotope tracing with 13C/15N-uridine can quantify catabolic flux through uridine phosphorylase and downstream uracil catabolism. This method measures how much uridine is degraded versus salvaged, and is essential for linking genotype to metabolic phenotype.

Pseudouridine sequencing (psi-seq) and tRNA modification profiling can detect changes in uridine-derived modifications. These methods are used to assess how uridine catabolism affects the epitranscriptome and translation.

Ribo-seq and polysome profiling measure translation efficiency in response to altered uridine availability. They are particularly useful for studying pseudouridine-mediated PKR suppression and mTORC1-dependent protein synthesis.

Genome-wide CRISPR knockout screens can identify genes required for uridine catabolism and resistance to uridine depletion. Such screens are applied to discover synthetic lethal interactions in cancer and immune cells.

Researchers studying uridine catabolic process-related genes often need to determine whether a candidate gene is causally involved in uridine breakdown, RNA modification, or immune cell function. CRISPR-based models provide a direct way to test loss-of-function, gain-of-function, and patient-specific mutations in relevant cell types.

GO:0006218 uridine catabolic process is a central metabolic pathway that controls uridine availability for RNA modification, glycosylation, and translation. Its dysregulation impacts cancer immunity, neuronal function, and pharmacological responses, as shown by studies on UPP1, CDA, CTU1/2, and pseudouridine synthases. Understanding this process requires integrated approaches including CRISPR models, metabolomics, and RNA modification profiling. EDITGENE provides comprehensive CRISPR services to dissect uridine catabolic process, from knockout and point mutation models to library screening and bioinformatics. By combining precise genome editing with functional assays, researchers can uncover causal roles of uridine catabolic genes in health and disease.